Drug news
Provenge sales for Prostate Cancer disappoint Dendreon and lead to staff reduction
Dendreon will reduce its workforce by 500 employees( about one-quarter of its work force)as sales of its prostate cancer immunotherapy, Provenge(sipuleucel-T) have disappointed and are well short of its projections. The largest proposed job cuts are in manufacturing but the company is looking for a partner in Europe as its moves toward filing for approval of Provenge there by the end of 2011.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins